NASDAQ:BIS - ProShares UltraShort Nasdaq Biotechnology Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $16.96 -0.34 (-1.97 %) (As of 08/21/2018 04:00 PM ET)Previous Close$17.30Today's Range$16.89 - $17.2852-Week Range$16.24 - $24.92Volume20,125 shsAverage Volume58,037 shsMarket Capitalization$31.22 millionP/E RatioN/ADividend Yield0.00%Beta-2.81 Company ProfileChartHeadlinesOptions ChainSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email ProShares Ultra Nasdaq Biotechnology (the Fund) seeks investment results for a single day only, not for longer periods. The Fund seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day's returns compounded over the period, which will very likely differ from twice (200%) the return of the Nasdaq Biotechnology Index (the Index) for that period. The Fund does not seek to achieve its stated investment objective over a period of time greater than one day. The Fund invests in equity securities and derivatives that have similar daily performance characteristics as twice (200%) the daily return of the Index. The Fund invests in financial instruments whose value is derived from the value of an underlying asset, interest rate or index. ProShare Advisors LLC is the investment advisor of the Fund. Receive BIS News and Ratings via Email Sign-up to receive the latest news and ratings for BIS and its competitors with MarketBeat's FREE daily newsletter. Basic Details Issuer ProShares Fund NameProShares UltraShort Nasdaq Biotechnology Tax ClassificationRegulated Investment Company SymbolNASDAQ:BIS Inception Date4/7/2010 Fund ManagerMichael Neches, Tarak Dave Webwww.proshares.com Phone+1-240-4976400 Fund Focus Asset ClassEquity BenchmarkNASDAQ Biotechnology TR USD CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Fund Statistics Assets Under Management$26.45 million Average Daily Volume$28,375.00 Discount/Premium-1.88% ETF Expenses Management Fee0.75% Other Expenses0.36% Total Expenses1.11% Fee Waiver-0.16% Net Expenses0.95%Administrator, Advisor and Custodian AdministratorJ.P. Morgan Investor Services Co. AdvisorProShare Advisors LLC CustodianJPMorgan Chase Bank, N.A. DistributorSEI Investments Distribution Co. Transfer AgentJPMorgan Chase Bank, N.A. Trustee Lead Market MakerVirtu Financial ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) Frequently Asked Questions What is ProShares UltraShort Nasdaq Biotechnology's stock symbol? ProShares UltraShort Nasdaq Biotechnology trades on the NASDAQ under the ticker symbol "BIS." Has ProShares UltraShort Nasdaq Biotechnology been receiving favorable news coverage? Media coverage about BIS stock has trended somewhat positive this week, Accern reports. Accern rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ProShares UltraShort Nasdaq Biotechnology earned a media and rumor sentiment score of 0.13 on Accern's scale. They also assigned press coverage about the company an impact score of 46.23 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. View Recent Headlines for ProShares UltraShort Nasdaq Biotechnology. Who are ProShares UltraShort Nasdaq Biotechnology's major shareholders? ProShares UltraShort Nasdaq Biotechnology's stock is owned by a number of of institutional and retail investors. Top institutional investors include Healthcare Value Capital LLC (8.40%), Jane Street Group LLC (1.05%), Virtu Financial LLC (0.84%) and HRT Financial LLC (0.64%). View Institutional Ownership Trends for ProShares UltraShort Nasdaq Biotechnology. Which major investors are selling ProShares UltraShort Nasdaq Biotechnology stock? BIS stock was sold by a variety of institutional investors in the last quarter, including Virtu Financial LLC. View Insider Buying and Selling for ProShares UltraShort Nasdaq Biotechnology. Which major investors are buying ProShares UltraShort Nasdaq Biotechnology stock? BIS stock was bought by a variety of institutional investors in the last quarter, including Healthcare Value Capital LLC, HRT Financial LLC and Jane Street Group LLC. View Insider Buying and Selling for ProShares UltraShort Nasdaq Biotechnology. How do I buy shares of ProShares UltraShort Nasdaq Biotechnology? Shares of BIS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is ProShares UltraShort Nasdaq Biotechnology's stock price today? One share of BIS stock can currently be purchased for approximately $16.96. How big of a company is ProShares UltraShort Nasdaq Biotechnology? ProShares UltraShort Nasdaq Biotechnology has a market capitalization of $31.22 million. How can I contact ProShares UltraShort Nasdaq Biotechnology? ProShares UltraShort Nasdaq Biotechnology's mailing address is SUITE 1000, 7501 WISCONSIN AVENUE, Bethesda, MD 20814, United States. The company can be reached via phone at +1-240-4976400. MarketBeat Community Rating for ProShares UltraShort Nasdaq Biotechnology (NASDAQ BIS)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 44 (Vote Outperform)Underperform Votes: 55 (Vote Underperform)Total Votes: 99MarketBeat's community ratings are surveys of what our community members think about ProShares UltraShort Nasdaq Biotechnology and other stocks. Vote "Outperform" if you believe BIS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 8/21/2018 by MarketBeat.com StaffFeatured Article: How do investors use RSI to grade stocks?